Current with legislation from the 2023 Regular and Special Sessions signed by the Governor as of November 21, 2023.
Section 1372.001 - Definitions In this chapter:
(1) "Biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. The term includes: (2) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. The term includes: (A) single-analyte tests; (B) multiplex panel tests; and (C) whole genome sequencing. (3) "Consensus statements" means statements that: (A) address specific clinical circumstances based on the best available evidence for the purpose of optimizing clinical care outcomes; and (B) are developed by an independent, multidisciplinary panel of experts that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy. (4) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that: (A) establish a standard of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options; (B) include recommendations intended to optimize patient care; and (C) are developed by an independent organization or medical professional society that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy. Tex. Ins. Code § 1372.001
Added by Acts 2023, Texas Acts of the 88th Leg.- Regular Session, ch. 279,Sec. 1, eff. 9/1/2023, app. only to a health benefit plan that is delivered, issued for delivery, or renewed on or after January 1, 2024.